<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0126016</article-id>
<article-id pub-id-type="publisher-id">PONE-D-14-54683</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies</article-title>
<alt-title alt-title-type="running-head">AASV and Cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Shang</surname>
<given-names>Weifeng</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ning</surname>
<given-names>Yong</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Xu</surname>
<given-names>Xiu</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Menglan</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Guo</surname>
<given-names>Shuiming</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Han</surname>
<given-names>Min</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Zeng</surname>
<given-names>Rui</given-names>
</name>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Ge</surname>
<given-names>Shuwang</given-names>
</name>
<xref rid="cor001" ref-type="corresp">*</xref>
<xref rid="aff001" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Xu</surname>
<given-names>Gang</given-names>
</name>
<xref rid="cor001" ref-type="corresp">*</xref>
<xref rid="aff001" ref-type="aff"/>
</contrib>
</contrib-group>
<aff id="aff001"><addr-line>Department of Nephrology, Tongji hospital affiliated to Tongji medical college, Huazhong University of Science and Technology, Wuhan, Hubei, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Kuwana</surname>
<given-names>Masataka</given-names>
</name>
<role>Academic Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Nippon Medical School Graduate School of Medicine, JAPAN</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: GX S. Ge. Performed the experiments: WS S. Ge YN. Analyzed the data: WS S. Ge YN RZ. Contributed reagents/materials/analysis tools: MH ML XX S. Guo. Wrote the paper: WS S. Ge MH.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">geshuwang@tjh.tjmu.edu.cn</email> (SG); <email xlink:type="simple">xugang@tjh.tjmu.edu.cn</email> (GX)</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>5</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<year>2015</year>
</pub-date>
<volume>10</volume>
<issue>5</issue>
<elocation-id>e0126016</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>12</month>
<year>2014</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>3</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Shang et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0126016" xlink:type="simple"/>
<abstract>
<sec id="sec001">
<title>Objective</title>
<p>The purpose of this paper is to examine cancer incidence in patients with ANCA-associated vasculitis (AASV) derived from population-based cohort studies by means of meta-analysis.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>Relevant electronic databases were searched for studies characterizing the associated risk of overall malignancy in patients with AASV. Standardized incidence rates (SIRs) with 95% confidence intervals (CIs) were used to evaluate the strength of association. We tested for publication bias and heterogeneity and stratified for site-specific cancers.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Six studies (n = 2,578) were eventually identified, of which six provided the SIR for overall malignancy, five reported the SIR for non-melanoma skin cancer (NMSC), four for leukemia, five for bladder cancer, three for lymphoma, three for liver cancer, four for lung cancer, three for kidney cancer, four for prostate cancer, four for colon cancer and four for breast cancer. Overall, the pooled SIR of cancer in AASV patients was 1.74 (95%CI = 1.37–2.21), with moderate heterogeneity among these studies (I<sup>2</sup> = 65.8%, P = 0.012). In sub-analyses for site-specific cancers, NMSC, leukemia and bladder cancer were more frequently observed in patients with AASV with SIR of 5.18 (95%CI = 3.47–7.73), 4.89 (95%CI = 2.93–8.16) and 3.84 (95%CI = 2.72–5.42) respectively. There was no significant increase in the risk of kidney cancer (SIR = 2.12, 95%CI = 0.66–6.85), prostate cancer (SIR = 1.45, 95%CI = 0.87–2.42), colon cancer (SIR = 1.26, 95%CI = 0.70–2.27), and breast cancer (SIR = 0.95, 95%CI = 0.50–1.79). Among these site-specific cancers, only NMSC showed moderate heterogeneity (I<sup>2</sup> = 55.8%, P = 0.06). No publication bias was found by using the Begg’s test and Egger's test.</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>This meta-analysis shows that AASV patients treatment with cyclophosphamide (CYC) are at increased risk of late-occurring malignancies, particularly of the NMSC, leukemia and bladder cancer. However, there is no significant association between AASV and kidney cancer, prostate cancer, colon cancer and breast cancer. These findings emphasize monitoring and preventative management in AASV patients after cessation of CYC therapy is momentous.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>This work was supported by the National Nature Science Foundation of China (NSFC) (No. 81200531 for Shuwang Ge; No. 81470948 and 81270770 for Gang Xu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="3"/>
<page-count count="11"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability" xlink:type="simple">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>The anti-neutrophil cytoplasm antibody associated vasculitides (AASVs), including graulomatosis with polyangiitis (GPA, Wegener’s granulomatosis) and microscopic polyangiitis (MPA), are a group of multisystem disorders characterized by necrotizing inflammation of small blood vessels[<xref rid="pone.0126016.ref001" ref-type="bibr">1</xref>]. Although, AASV involves small vessels with predilection for the kidneys, lungs, and peripheral nervous system in most of the patients, any organ system can be affected. The disease usually presents in the middle aged or elderly, with a peak incidence of 65 per million/year in those aged 65–74 years[<xref rid="pone.0126016.ref002" ref-type="bibr">2</xref>]. There is a reported mortality of 80% at 1 year in untreated patients[<xref rid="pone.0126016.ref002" ref-type="bibr">2</xref>]. Since the late 1970s, the introduction of glucocorticoids and cyclophosphamide (CYC) as standard treatments has improved the prognosis considerably[<xref rid="pone.0126016.ref003" ref-type="bibr">3</xref>]. An analysis of four multicenter trials reported cumulative survival at 1, 2 and 5 years of 88%, 85% and 78%, respectively[<xref rid="pone.0126016.ref004" ref-type="bibr">4</xref>]. With standard therapy regimen, remission can be induced in about 70–90% of patients[<xref rid="pone.0126016.ref005" ref-type="bibr">5</xref>]. Nevertheless, 25–50% of the patients will relapse[<xref rid="pone.0126016.ref006" ref-type="bibr">6</xref>], leading to increased duration and quantity of CYC which would cause toxic effects especially for cardiovascular and cancer morbidity[<xref rid="pone.0126016.ref007" ref-type="bibr">7</xref>]. The latter has drawn more attention recently. Much effort has been devoted to this field which demonstrated the SIRs for overall cancer has increased to more than 1.6 associated with AASV[<xref rid="pone.0126016.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>–<xref rid="pone.0126016.ref013" ref-type="bibr">13</xref>], but the risk of overall cancer appeared to be somewhat reduced in one study (SIR = 0.8, 95%CI = 0.5–1.4)[<xref rid="pone.0126016.ref014" ref-type="bibr">14</xref>]. Moreover, cancer type-specific analyses demonstrated an significantly increased risk of non-melanoma skin cancer (NMSC)[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>–<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>], leukemia[<xref rid="pone.0126016.ref009" ref-type="bibr">9</xref>–<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>], and bladder cancer[<xref rid="pone.0126016.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0126016.ref009" ref-type="bibr">9</xref>–<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0126016.ref015" ref-type="bibr">15</xref>] in some studies. However, the reported risk is different. Recently, the comprehensive review performed by Mahr et al.[<xref rid="pone.0126016.ref016" ref-type="bibr">16</xref>] has shown the current understanding of the potential link between AASV and the occurrence of cancer, but no meta-analysis has been used to examine the relationship. Given the fact that individual studies may have insufficient statistical power because of sample size, therefore, we undertook the present meta-analysis to quantitatively confirm the incidence of cancer in AASV patients versus the general population, which may provide a realistic perspective on risk in the clinical setting.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="sec007">
<title>Search strategy and study selection</title>
<p>A PubMed and EMBASE databases were searched systematically for all articles published before September 1st, 2014. The search terms used were “cancer and ANCA-associated vasculitis”,“cancer and AASV”,“cancer and WG”,“cancer and GPA”,“cancer and MPA”, “epidemiology and ANCA-associated vasculitis”. Two investigators (WS and SG), using these parameters, independently filtered out all the eligible articles and hand-searched references of retrieved papers for additional available studies. We did not include unpublished or abstract only publications. No restriction was placed on language. Conflicting results were resolved by consensus and endnote was used to merge retrieved citations.</p>
</sec>
<sec id="sec008">
<title>Inclusion criteria</title>
<p>Included studies met the following criteria: (1) they were cohort studies that estimating the influence of AASV on cancer risk with odds ratio (OR), risk ratio (RR), hazard ratio (HR), or standardized incidence/mortality rate(SIR/SMR) and their 95% confidence intervals (CIs) of overall cancer. (2) defined AASV as one of the exposure interests and cancer as one of the outcome of interests.</p>
</sec>
<sec id="sec009">
<title>Exclusion criteria</title>
<p>The exclusion criteria included: reviews, case reports, conference publications, cross-sectional studies, studies limiting the population age, studies not specifying the types of tumor, and studies focusing on demonstrate incidence of cancer before the diagnosis of AASV. If a cohort study was reported in more than one publication, we chose the largest sample size or the latest article.</p>
</sec>
<sec id="sec010">
<title>Data extraction and Quality evaluation</title>
<p>The following data were extracted independently by two investigators (WS and SG) from the included studies: the authors, publication year, country, study design, AASV phenotypes studied, period of follow-up, mean/median observation period, cumulative observation period, number of patients studied, number of cancers observed in the cohort, patients’ gender and age, and SIR with its 95% CI, gender of cancer patients, main therapy. When needed, we contacted the original author for clarification. This study complied with meta-analysis of observational studies in Epidemiology (<xref rid="pone.0126016.s001" ref-type="supplementary-material">S1 MOOSE Checklist</xref>)[<xref rid="pone.0126016.ref017" ref-type="bibr">17</xref>]. The quality of each study was independently evaluated by two investigators (WS and SG) using the Newcastle-Ottawa Scale (NOS)[<xref rid="pone.0126016.ref018" ref-type="bibr">18</xref>]. The NOS, including selection, comparability and outcome, is a scale for assessing the quality of published non-randomized studies. The study which met at least five NOS criteria was considered to be a high quality study. Discrepancies between investigators were solved by consensus.</p>
</sec>
<sec id="sec011">
<title>Data Synthesis and Analysis</title>
<p>In this meta-analysis, we collected SIR with 95%CI to combine the data and assessed heterogeneity of the mean difference with the Chi-squared based Q-statistic test. If the P value of the heterogeneity Q-statistic was less than 0.10, the random-effects model was used to calculate the pooled SIRs[<xref rid="pone.0126016.ref019" ref-type="bibr">19</xref>]. On the contrary, the fixed-effects model was selected[<xref rid="pone.0126016.ref020" ref-type="bibr">20</xref>]. We also quantified the effect of heterogeneity using the I<sup>2</sup> index[<xref rid="pone.0126016.ref021" ref-type="bibr">21</xref>]. I<sup>2</sup> values of 25%, 50% and 75% indicate low, moderate and severe statistical heterogeneity, respectively. Publication bias was evaluated using the Begg’s test and Egger’s test[<xref rid="pone.0126016.ref022" ref-type="bibr">22</xref>,<xref rid="pone.0126016.ref023" ref-type="bibr">23</xref>]. P value &lt;0.10 was considered significant. All analyses were performed in Stata 10.0 (College Station, TX, USA).</p>
</sec>
</sec>
<sec id="sec012" sec-type="results">
<title>Results</title>
<sec id="sec013">
<title>Studies included in the meta-analysis</title>
<p>As shown in <xref rid="pone.0126016.g001" ref-type="fig">Fig 1</xref>, our initial search rendered 2,762 potentially relevant articles, from which six cohort studies were included[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>–<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0126016.ref014" ref-type="bibr">14</xref>]. Three studies were monocentric cohorts[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0126016.ref014" ref-type="bibr">14</xref>], two study nationwide registry linkage[<xref rid="pone.0126016.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>], and one was a multinational study[<xref rid="pone.0126016.ref011" ref-type="bibr">11</xref>]. Among these studies, two were carried out in Sweden, one in Germany, one in Poland, one in Denmark and one in Europe and Mexico. They were published between 1998 and 2013. Mean or median observation period for ascertained cases ranged from 4.58 to 7 years. In this meta-analysis, we are including 258 cases of cancers identified in a total cohort of 2,578 individuals, 1,191 women (46%) and 1,387 men (54%), with a diagnosis of AASV selected characteristics of the included studies are shown in <xref rid="pone.0126016.t001" ref-type="table">Table 1</xref>. While <xref rid="pone.0126016.t002" ref-type="table">Table 2</xref> shows the detailed ratings of study quality for NOS.</p>
<fig id="pone.0126016.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0126016.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Literature search flow diagram.</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0126016.g001" position="float" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0126016.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0126016.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of studies of ANCA-associated vasculitis (AASV) and cancer incidence.</title></caption>
<alternatives>
<graphic id="pone.0126016.t001g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0126016.t001" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Author(year)</th>
<th align="left" rowspan="1" colspan="1">Westman et al. 1998[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>]</th>
<th align="left" rowspan="1" colspan="1">Knight et al. 2002[<xref rid="pone.0126016.ref009" ref-type="bibr">9</xref>]</th>
<th align="left" rowspan="1" colspan="1">Faurschou et al. 2008[<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>]</th>
<th align="left" rowspan="1" colspan="1">Holle et al. 2011[<xref rid="pone.0126016.ref014" ref-type="bibr">14</xref>]</th>
<th align="left" rowspan="1" colspan="1">Heijl et al. 2011[<xref rid="pone.0126016.ref011" ref-type="bibr">11</xref>]</th>
<th align="left" rowspan="1" colspan="1">Zycinska et al. 2013[<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>]</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Country</td>
<td align="left" rowspan="1" colspan="1">Sweden</td>
<td align="left" rowspan="1" colspan="1">Sweden</td>
<td align="left" rowspan="1" colspan="1">Denmark</td>
<td align="left" rowspan="1" colspan="1">Germany</td>
<td align="left" rowspan="1" colspan="1">Europe, Mexico</td>
<td align="left" rowspan="1" colspan="1">Poland</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Study design</td>
<td align="left" rowspan="1" colspan="1">Monocenter clinical cohort study</td>
<td align="left" rowspan="1" colspan="1">nationwide hospital discharge database study</td>
<td align="left" rowspan="1" colspan="1">nationwide hospital discharge database study</td>
<td align="left" rowspan="1" colspan="1">monocenter clinical cohort study</td>
<td align="left" rowspan="1" colspan="1">multicenter clinical trials</td>
<td align="left" rowspan="1" colspan="1">monocenter clinical cohort study</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">AASV phenotypes studied</td>
<td align="left" rowspan="1" colspan="1">GPA /MPA</td>
<td align="left" rowspan="1" colspan="1">GPA</td>
<td align="left" rowspan="1" colspan="1">GPA</td>
<td align="left" rowspan="1" colspan="1">GPA</td>
<td align="left" rowspan="1" colspan="1">GPA /MPA</td>
<td align="left" rowspan="1" colspan="1">Pulmonary vasculitis</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Follow-up period</td>
<td align="left" rowspan="1" colspan="1">1971–1993</td>
<td align="left" rowspan="1" colspan="1">1969–1994</td>
<td align="left" rowspan="1" colspan="1">1973–1999</td>
<td align="left" rowspan="1" colspan="1">1966–2005</td>
<td align="left" rowspan="1" colspan="1">1995–2007</td>
<td align="left" rowspan="1" colspan="1">1990–2008</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Mean/median observation period, years</td>
<td align="left" rowspan="1" colspan="1">4.58</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">4.95</td>
<td align="left" rowspan="1" colspan="1">7</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cumulative observation period, person-year</td>
<td align="left" rowspan="1" colspan="1">944</td>
<td align="left" rowspan="1" colspan="1">5708</td>
<td align="left" rowspan="1" colspan="1">2121</td>
<td align="left" rowspan="1" colspan="1">2572</td>
<td align="left" rowspan="1" colspan="1">2650</td>
<td align="left" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Patients with AASV, n</td>
<td align="left" rowspan="1" colspan="1">123</td>
<td align="left" rowspan="1" colspan="1">1065</td>
<td align="left" rowspan="1" colspan="1">293</td>
<td align="left" rowspan="1" colspan="1">445</td>
<td align="left" rowspan="1" colspan="1">535</td>
<td align="left" rowspan="1" colspan="1">117</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Gender, % male</td>
<td align="left" rowspan="1" colspan="1">64.2%</td>
<td align="left" rowspan="1" colspan="1">53%</td>
<td align="left" rowspan="1" colspan="1">53.2%</td>
<td align="left" rowspan="1" colspan="1">50.1%</td>
<td align="left" rowspan="1" colspan="1">53.8%</td>
<td align="left" rowspan="1" colspan="1">67%</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Medium/Mean age, years</td>
<td align="left" rowspan="1" colspan="1">61.8</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">59</td>
<td align="left" rowspan="1" colspan="1">51.7</td>
<td align="left" rowspan="1" colspan="1">57.7</td>
<td align="left" rowspan="1" colspan="1">64.5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cancer(following the Diagnosis of AASV), n</td>
<td align="left" rowspan="1" colspan="1">15</td>
<td align="left" rowspan="1" colspan="1">110</td>
<td align="left" rowspan="1" colspan="1">50</td>
<td align="left" rowspan="1" colspan="1">18</td>
<td align="left" rowspan="1" colspan="1">50</td>
<td align="left" rowspan="1" colspan="1">15</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SIR and 95%CI</td>
<td align="left" rowspan="1" colspan="1">1.6 (0.9–2.7)</td>
<td align="left" rowspan="1" colspan="1">2.0 (1.7–2.5)</td>
<td align="left" rowspan="1" colspan="1">2.1 (1.5–2.7)</td>
<td align="left" rowspan="1" colspan="1">0.8 (0.5–1.4)</td>
<td align="left" rowspan="1" colspan="1">1.6 (1.2–2.1)</td>
<td align="left" rowspan="1" colspan="1">2.5 (1.2–2.9)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Gender of cancer patients, % male or SIR</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">SIR 2.1</td>
<td align="left" rowspan="1" colspan="1">NR</td>
<td align="left" rowspan="1" colspan="1">SIR 1.12</td>
<td align="left" rowspan="1" colspan="1">63.0%</td>
<td align="left" rowspan="1" colspan="1">NR</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Main therapy</td>
<td align="left" rowspan="1" colspan="1">CYC/GC</td>
<td align="left" rowspan="1" colspan="1">CYC/GC</td>
<td align="left" rowspan="1" colspan="1">CYC/GC</td>
<td align="left" rowspan="1" colspan="1">CYC/GC</td>
<td align="left" rowspan="1" colspan="1">CYC/GC</td>
<td align="left" rowspan="1" colspan="1">CYC/GC</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Abbreviations: NR, not reported; SIR, standardized incidence rate; CI,confidence interval; GPA, graulomatosis with polyangiitis; MPA, microscopic polyangiitis; CYC, cyclophosphamide; GC, glucocorticoids.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0126016.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0126016.t002</object-id>
<label>Table 2</label> <caption><title>Assessment of study quality.</title></caption>
<alternatives>
<graphic id="pone.0126016.t002g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0126016.t002" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">References</th>
<th colspan="9" align="center" rowspan="1">Quality indications form of Newcastle-Ottawa Scale</th>
<th align="left" rowspan="1" colspan="1">Total stars</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1"/>
<th align="left" rowspan="1" colspan="1">1</th>
<th align="left" rowspan="1" colspan="1">2</th>
<th align="left" rowspan="1" colspan="1">3</th>
<th align="left" rowspan="1" colspan="1">4</th>
<th align="left" rowspan="1" colspan="1">5a</th>
<th align="left" rowspan="1" colspan="1">5b</th>
<th align="left" rowspan="1" colspan="1">6</th>
<th align="left" rowspan="1" colspan="1">7</th>
<th align="left" rowspan="1" colspan="1">8</th>
<th align="left" rowspan="1" colspan="1"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Westman et al. 1998[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>]</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">9</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Knight et al. 2002[<xref rid="pone.0126016.ref009" ref-type="bibr">9</xref>]</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">No</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Faurschou et al. 2008[<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>]</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">No</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Holle et al. 2011[<xref rid="pone.0126016.ref014" ref-type="bibr">14</xref>]</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">No</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">No</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">7</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Heijl et al. 2011[<xref rid="pone.0126016.ref011" ref-type="bibr">11</xref>]</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">No</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">8</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Zycinska et al. 2013[<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>]</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">No</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">Yes</td>
<td align="left" rowspan="1" colspan="1">No</td>
<td align="left" rowspan="1" colspan="1">No</td>
<td align="left" rowspan="1" colspan="1">No</td>
<td align="left" rowspan="1" colspan="1">5</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>For cohort studies: 1, representativeness of exposed cohort; 2, selection of the nonexposed cohort; 3, ascertainment of exposure; 4, outcome of interest not present at start; 5a, cohorts comparable on basis of main factor; 5b, cohorts comparable on any additional factor; 6, assessment of outcome with independency; 7, follow-up long enough for outcomes to occur; 8, complete accounting for cohorts or subjects lost to follow-up unlikely to introduce bias.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec014">
<title>Overall cancer risk in AASV</title>
<p>The SIR of cancers within the six individual study populations ranged between 0.8 and 2.5, with an overall meta-analytical SIR of 1.74 (95%CI = 1.37–2.21), and the heterogeneity was moderate (I<sup>2</sup> = 65.8%, P = 0.012). The forest plot of SIR is shown in <xref rid="pone.0126016.g002" ref-type="fig">Fig 2</xref>.</p>
<fig id="pone.0126016.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0126016.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Forest plot of association between ANCA-associated vasculitis (AASV) and overall cancer.</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0126016.g002" position="float" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec015">
<title>Organ-specific Cancer Associated with AASV</title>
<p>We performed subgroup analyses for all site specific cancers that have been reported by more than one included study (<xref rid="pone.0126016.t003" ref-type="table">Table 3</xref>). This subgroup analyses did not show evidence of significant heterogeneity (I<sup>2</sup> = 0) except for the NMSC (I<sup>2</sup> = 55.8%, P = 0.06). The result revealed that NMSC, leukemia and bladder cancer were more frequently observed in patients with AASV than in the entire population, with SIR of 5.18 (95%CI = 3.47–7.73), 4.89 (95%CI = 2.93–8.16) and 3.84 (95%CI = 2.72–5.42) respectively, followed by lymphoma (SIR = 3.79, 95%CI = 1.87–7.69), liver cancer (SIR = 3.50, 95%CI = 1.45–8.43), lung cancer (SIR = 1.67, 95%CI = 1.07–2.60). However, there was no significant increase in the risk of kidney cancer (SIR = 2.12, 95%CI = 0.66–6.85), prostate cancer (SIR = 1.45, 95%CI = 0.87–2.42), colon cancer (SIR = 1.25, 95%CI = 0.66–2.38), and breast cancer (SIR = 0.95, 95%CI = 0.50–1.79). In organ-specific cancer with only one study, formal meta-analyses were not performed. However, it is still worth noting that the greatly high SIRs for cancers of the testis (45.7)[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>], vulva (32.9)[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>] and nose and ear (14.1)[<xref rid="pone.0126016.ref009" ref-type="bibr">9</xref>] reported relating to AASV.</p>
<table-wrap id="pone.0126016.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0126016.t003</object-id>
<label>Table 3</label> <caption><title>Pooled site-specific cancer risks in patients with ANCA-associated vasculitis (AASV).</title></caption>
<alternatives>
<graphic id="pone.0126016.t003g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0126016.t003" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Site-specific cancers</th>
<th align="left" rowspan="1" colspan="1">References(no.of studies)</th>
<th align="left" rowspan="1" colspan="1">Pooled SIR (95% CI)<xref rid="t003fn001" ref-type="table-fn"><sup>a</sup></xref></th>
<th colspan="2" align="center" rowspan="1">Heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"><bold>I</bold><sup><bold>2</bold></sup><bold>(%)</bold><xref rid="t003fn002" ref-type="table-fn"><sup><bold>b</bold></sup></xref></td>
<td align="left" rowspan="1" colspan="1"><bold>P value(Q test)</bold><xref rid="t003fn003" ref-type="table-fn"><sup><bold>c</bold></sup></xref></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Non-melanoma skin cancer</td>
<td align="left" rowspan="1" colspan="1">Westman et al.(1998), Knight et al.(2002), Faurschou et al.(2008),Heijl et al.(2011), Zycinska et al.(2013). (5)</td>
<td align="left" rowspan="1" colspan="1">5.18(3.47–7.73)</td>
<td align="left" rowspan="1" colspan="1">55.8%</td>
<td align="char" char="." rowspan="1" colspan="1">0.060</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Leukemia</td>
<td align="left" rowspan="1" colspan="1">Knight et al.(2002), Faurschou et al. (2008), Heijl et al.(2011), Zycinska et al.(2013). (4)</td>
<td align="left" rowspan="1" colspan="1">4.89(2.93–8.16)</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="char" char="." rowspan="1" colspan="1">0.909</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Bladder</td>
<td align="left" rowspan="1" colspan="1">Westman et al.(1998), Knight et al.(2002), Faurschou et al.(2008),Heijl et al.(2011), Zycinska et al.(2013). (5)</td>
<td align="left" rowspan="1" colspan="1">3.84(2.72–5.42)</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="char" char="." rowspan="1" colspan="1">0.809</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lymphoma</td>
<td align="left" rowspan="1" colspan="1">Westman et al.(1998), Knight et al.(2002), Heijl et al.(2011). (3)</td>
<td align="left" rowspan="1" colspan="1">3.79(1.87–7.69)</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="char" char="." rowspan="1" colspan="1">0.639</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Liver</td>
<td align="left" rowspan="1" colspan="1">Knight et al.(2002), Faurschou et al. (2008), Heijl et al.(2011).(3)</td>
<td align="left" rowspan="1" colspan="1">3.50(1.45–8.43)</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="char" char="." rowspan="1" colspan="1">0.871</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lung</td>
<td align="left" rowspan="1" colspan="1">Knight et al.(2002), Faurschou et al.(2008), Heijl et al.(2011), Zycinska et al.(2013). (4)</td>
<td align="left" rowspan="1" colspan="1">1.67(1.07–2.60)</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="char" char="." rowspan="1" colspan="1">0.915</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Kidney<xref rid="t003fn005" ref-type="table-fn"><sup>e</sup></xref></td>
<td align="left" rowspan="1" colspan="1">Westman et al.(1998), Knight et al.(2002).(2)</td>
<td align="left" rowspan="1" colspan="1">2.12(0.66–6.85)</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="char" char="." rowspan="1" colspan="1">0.711</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Prostate</td>
<td align="left" rowspan="1" colspan="1">Westman et al.(1998), Knight et al.(2002), Faurschou et al. (2008), Heijl et al.(2011). (4)</td>
<td align="left" rowspan="1" colspan="1">1.44(0.88–2.34)</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="char" char="." rowspan="1" colspan="1">0.395</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Colon </td>
<td align="left" rowspan="1" colspan="1">Knight et al.(2002), Faurschou et al.(2008), Heijl et al.(2011)<xref rid="t003fn004" ref-type="table-fn"><sup>d</sup></xref>, Zycinska et al.(2013). (4)</td>
<td align="left" rowspan="1" colspan="1">1.26(0.70–2.27)</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="char" char="." rowspan="1" colspan="1">0.642</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Breast</td>
<td align="left" rowspan="1" colspan="1">Westman et al.(1998), Knight et al.(2002), Faurschou et al. (2008), Heijl et al.(2011). (4)</td>
<td align="left" rowspan="1" colspan="1">0.95(0.50–1.79)</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="char" char="." rowspan="1" colspan="1">0.671</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p><sup>a</sup> Standardized incidence rate and 95% confidence interval</p></fn>
<fn id="t003fn002"><p><sup>b</sup> Percentage of total variation attributable to statistical heterogeneity between studies (25%, low; 50%, moderate; 75%, high)</p></fn>
<fn id="t003fn003"><p><sup>c</sup> P value for heterogeneity among studies assessed with Chi-squared based Q test</p></fn>
<fn id="t003fn004"><p><sup>d</sup> Colorectal cancer</p></fn>
<fn id="t003fn005"><p><sup>e</sup> One of three cannot be merged.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec016">
<title>Sensitivity analysis</title>
<p>The results of this meta-analysis were not affected by sensitivity analysis, which were performed by excluding one study at a time. When any individual study was excluded, the corresponding pooled SIRs were not substantially altered (data not shown). The statistically similar results indicated this meta-analysis was relatively stable.</p>
</sec>
<sec id="sec017">
<title>Heterogeneity and reporting bias</title>
<p>In the overall cancer and NMSC groups, moderate heterogeneity between studies was observed (all P &lt;0.10). When the study by Holle et al.[<xref rid="pone.0126016.ref014" ref-type="bibr">14</xref>] was deleted, the P value of heterogeneity for the overall cancer group was 0.414, indicating that this study may be the source of heterogeneity in the overall cancer group. As for the NMSC group, the P value of heterogeneity was 0.395 after removing the study by Heijl et al.[<xref rid="pone.0126016.ref011" ref-type="bibr">11</xref>]. The study might contribute to the heterogeneity in the the NMSC group.</p>
<p>The P value for Begg’s test was 0.707 (continuity corrected) and that for Egger’s test was 0.367, suggesting a low probability of publication bias.</p>
</sec>
</sec>
<sec id="sec018" sec-type="conclusions">
<title>Discussion</title>
<p>To the best of our knowledge, this study is the first meta-analysis to present cancer incidence in patients with AASV. We confirmed AASV was associated with an increased risk of cancer with a SIR of 1.74 (95%CI = 1.37–2.21).</p>
<p>There was an moderate heterogeneity in this meta-analysis. We consider that the main source of heterogeneity was the difference in follow-up time, as the mean follow-up varied in the studies. Heijl et al.[<xref rid="pone.0126016.ref011" ref-type="bibr">11</xref>] reported that cumulative overall cancer incidence rates were 8% and 13% at 5 and 8 years, respectively. In addition, the study by Holle et al.[<xref rid="pone.0126016.ref014" ref-type="bibr">14</xref>] would play an important part in heterogeneity. When the study was excluded, the heterogeneity disappeared. An increased incidence of malignancies in AASV was not found in the study[<xref rid="pone.0126016.ref014" ref-type="bibr">14</xref>], which may also be partly explained by the strict use of mesna to avoid bladder cancer and by the shorter average follow-up period of 3.9 years from cohort 3 than that in other cohorts. What’s more, different AASV types and sex ratio might contribute to the heterogeneity in our study. About 65% of the samples were patients with the GPA[<xref rid="pone.0126016.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0126016.ref014" ref-type="bibr">14</xref>], 24% were with mixed GPA/MPA[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0126016.ref011" ref-type="bibr">11</xref>], and others with Pulmonary vasculitis[<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>]. The reported SIRs for cancers at all sites were 1.92(95%CI = 1.31–2.71) and 1.20(95%CI = 0.71–1.89) for GPA and MPA, respectively[<xref rid="pone.0126016.ref011" ref-type="bibr">11</xref>]. Interestingly, men had a slightly higher relative risk of cancer than women[<xref rid="pone.0126016.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0126016.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0126016.ref014" ref-type="bibr">14</xref>]. Last, immune inhibitors and its dosage were also the source of heterogeneity. In the material presented by Heijl et al.[<xref rid="pone.0126016.ref011" ref-type="bibr">11</xref>], the lower CYC exposure, the lower SIR for cancers in any site. Similarly, Faurschou et al.[<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>] found that the risk of these malignancies was not increased for patients who never received CYC or for patients treated with cumulative CYC doses ≤ 36 g. Furthermore, Silva et al.[<xref rid="pone.0126016.ref013" ref-type="bibr">13</xref>] found SIR for solid malignancies of 3.92 (95% CI = 1.69–7.72) in the etanercept group among WG patients as compared to the general population, suggesting malignancy with a strong association with etanercept use.</p>
<p>We also observed a strongly increased risk of cancer in this paper, the risk being most pronounced for NMSC, leukemia and bladder cancer.</p>
<p>In regard to NMSC in this meta-analysis, a 5.18–7.73-fold increased risk is seen in AASV patients compared to the general population. The observed association between AASV and NMSC may result from the following major aspects. Firstly, most of the skin cancers occurred in sun-exposed areas, typically in the facial region[<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>], explained by that ultraviolet light is the main environmental cause of NMSC. Secondly, the direct causal association of AASV with NMSC may be mediated by intense immunosuppressive therapy[<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>]. For example, in the Westman et al.’s study[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>], no case of skin cancer was observed during the first year of follow-up, however, the risk for NMSC was significantly associated with azathioprine therapy for more than 12 mouths (16-fold increase) and with glucocorticoids for more than 48 mouths (20-fold increase). Alternatively, subsequent studies in AASV were consistent with observations in the Westman et al.’s study[<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>,<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>]. Furthermore, one study found that azathioprine might hasten the induction of NMSC by sensitising the skin cell genome to ultraviolet A radiation[<xref rid="pone.0126016.ref024" ref-type="bibr">24</xref>]. Therefore, patients with AASV should reduce sun exposure and use sun block regularly to decrease the risk of NMSC.</p>
<p>With respect to leukemia risk, the results suggest an approximate 4.89 to 8.16 increased risk in patients with AASV. Some studies revealed a high risk of leukemia following treatment with CYC in AASV patients, and the risk of secondary malignancies was shown to be dependent upon the cumulative dose of CYC received[<xref rid="pone.0126016.ref025" ref-type="bibr">25</xref>]. Faurschou et al.[<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>] has demonstrated a 59-fold increased SIR of acute myeloid leukemia (AML) in patients treated with a cumulative dose of CYC &gt; 36 g. In contrast, no case of leukemia due to milder or shorter duration of immunosuppression was found in the study by Westman et al.[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>]. Besides, in the material presented by Faurschou et al.[<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>], the high risk of AML (SIR = 19.6, 95%CI = 4.0–57) was observed, with long latency periods of seven to sixteen years. This finding is in agreement with observations by Zycinska and colleagues, who demonstrated the risk of leukemia significantly increasing between 5 and 10 years of the follow-up observation[<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>]. Consequently, Patients with AASV should undergo the long-term follow-up with blood routine examination after CYC therapy to early detection of leukemia.</p>
<p>There is an increased SIR of bladder cancer (SIR = 3.84, 95%CI = 2.72–5.42) without heterogeneity (I<sup>2</sup> = 0, P = 0.809). Our study and several studies[<xref rid="pone.0126016.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0126016.ref015" ref-type="bibr">15</xref>] have demonstrated that the risk for bladder cancer was associated with the cumulative dose of CYC administered. Indeed, Hoffman et al.[<xref rid="pone.0126016.ref006" ref-type="bibr">6</xref>] reported a 33-fold and Talar-Williams et al.[<xref rid="pone.0126016.ref015" ref-type="bibr">15</xref>] a 31-fold increased risk for bladder cancer described in a cohort of WG patients followed at the NIH (National Institutes of Health, Bethesda, Maryland). The higher incidence of bladder carcinomas among the NIH patients might reflect that these patients generally received higher cumulative doses of CYC (&gt;50 g for 64% of patients) than the patients (24% of patients) in Faurschou et al.’s study[<xref rid="pone.0126016.ref010" ref-type="bibr">10</xref>]. Besides, bladder cancers have been reported by another study with, like observations in hematology, a median latency period of 10.4 year after a first CYC exposure[<xref rid="pone.0126016.ref012" ref-type="bibr">12</xref>]. Other factors may have contributed to predict the development of bladder cancer in AASV. Microscopic non-glomerular hematuria has been recognised to be statistically significantly associated with the development of bladder cancer[<xref rid="pone.0126016.ref015" ref-type="bibr">15</xref>]. Although a history of smoking tobacco was not found to be an independent risk factor for the development of bladder cancer, tobacco smokers may develop bladder cancer at lower doses and earlier than non-smokers[<xref rid="pone.0126016.ref015" ref-type="bibr">15</xref>]. These results contribute to defining risk populations who should benefit from close and prolonged screening for bladder cancer. Moreover, oral administration of CYC was also an important predictor of increased bladder cancer risk, as a result of a French study[<xref rid="pone.0126016.ref026" ref-type="bibr">26</xref>]. It is also recommended that intravenous CYC should be systematically co-prescribed with mesna and hyperhydration and additional mesna prescription should be considered for oral CYC with prolonged treatment (&gt;4–6 months)[<xref rid="pone.0126016.ref027" ref-type="bibr">27</xref>].</p>
<p>The results of our meta-analysis show no statistically significant association between AASV and kidney cancer, prostate cancer, colon cancer and breast cancer. Interestingly, kidney cancer is of note. Although its CI is wide and include the null value, either misclassification or surveillance-related bias can not be excluded, the finding may declare a carcinogenic effect of the disease process itself, as previously indicated by case reports[<xref rid="pone.0126016.ref028" ref-type="bibr">28</xref>]. In addition, studies of AASV reported strikingly high SIRs for cancers of the testis[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>], vulva[<xref rid="pone.0126016.ref008" ref-type="bibr">8</xref>] and nose and ear[<xref rid="pone.0126016.ref009" ref-type="bibr">9</xref>], which relied on single cases and may reflect chance findings. Although not addressed in our study, the incidence of cervical neoplasia is increased in other diseases treated with immunosuppressants[<xref rid="pone.0126016.ref029" ref-type="bibr">29</xref>]. Thus, cervical screening is of great importance in women exposed to immunosuppressive therapies.</p>
<p>Several potential reasons relating to AASV that cause the increased SIRs for cancers are listed as follows. First, the used cytotoxic (predominantly CYC) therapy may increase the risk of malignancy. And in agreement of our finding, an umbrella review of 74 meta-analyses demonstrated commonly used medications including CYC may have potential increased risk of cancer[<xref rid="pone.0126016.ref030" ref-type="bibr">30</xref>]. Therefore, we should select a rational approach for different disease scenarios (try to avoid overuse of CYC) and focus on adverse effects of therapy[<xref rid="pone.0126016.ref031" ref-type="bibr">31</xref>]. Second, the dysfunction in immune system may raise the cancer risk[<xref rid="pone.0126016.ref032" ref-type="bibr">32</xref>]. Third, longstanding immune activation in patients with AASV may be oncogenic[<xref rid="pone.0126016.ref033" ref-type="bibr">33</xref>]. Fourth, vasculitis may be a paraneoplastic phenomenon, for instance, polyarteritis nodosa have been described in association with hairycell leukemia, owing to starting at the same time, concurrently improvement and the same nature[<xref rid="pone.0126016.ref034" ref-type="bibr">34</xref>]. Finally, some reports of cancer in association with AASV might be attributable to a coincidental association related to detection bias.</p>
<p>Several limitations of this meta-analysis should be acknowledged. Firstly, moderate heterogeneity was detected in the overall cancer and NMSC groups and publication bias, selection bias and a residual confounding bias may have existed although we cannot evaluate these hypotheses. Secondly, all of the studies included were partially representative as western countries with the Caucasian, and therefore, extrapolating results to other parts of the world should be interpreted cautiously. Thirdly, this meta-analysis included studies with different designs, observation period and sample size, which could introduce inherent limitations. Fourthly, due to limited data, we could not assess some confounding factors such as age and smoke. Fifthly, ANCA are now widely used as diagnostic markers for AASV, which may result in the early diagnosis of AASV, therefore it might have some bias in our final conclusions. Lastly, we could not judge whether cancer was a potential trigger or cause of AASV or a mere coincidence.</p>
<p>In summary, our study confirms a high incidence of cancer in the AASV population, specifically for NMSC, leukemia and bladder cancer, which might be associated with CYC use, particularly higher cumulative doses. Therefore the close follow-up is required. Periodic urine analysis, blood analysis and cervical screening should be performed. And smoking cessation and avoiding sun exposure simultaneously are recommended. Cystoscopy, bladder ultrasonography and skin biopsies should be advised in necessity. Further investigations are required to extract the accurate relations for the cancer risk to the cumulative doses. There is a continuing need for effective alternatives to toxic CYC treatment. Future studies should also focus on the underlying mechanisms between AASV and cancer risk.</p>
</sec>
<sec id="sec019">
<title>Supporting Information</title>
<supplementary-material id="pone.0126016.s001" xlink:href="info:doi/10.1371/journal.pone.0126016.s001" mimetype="application/msword" position="float" xlink:type="simple">
<label>S1 MOOSE Checklist</label>
<caption>
<title>MOOSE Checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0126016.s002" xlink:href="info:doi/10.1371/journal.pone.0126016.s002" mimetype="application/msword" position="float" xlink:type="simple">
<label>S1 PRISMA Checklist</label>
<caption>
<title>PRISMA Checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0126016.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jennette</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Falk</surname> <given-names>RJ</given-names></name>, <name name-style="western"><surname>Hu</surname> <given-names>P Xiao H</given-names></name> (<year>2013</year>) <article-title>Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis</article-title>. <source>Annu Rev Pathol</source> <volume>8</volume>: <fpage>139</fpage>–<lpage>160</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1146/annurev-pathol-011811-132453" xlink:type="simple">10.1146/annurev-pathol-011811-132453</ext-link></comment> <object-id pub-id-type="pmid">23347350</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Scott</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Watts</surname> <given-names>RA</given-names></name> (<year>2013</year>) <article-title>Epidemiology and clinical features of systemic vasculitis</article-title>. <source>Clin Exp Nephrol</source> <volume>17</volume>: <fpage>607</fpage>–<lpage>610</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10157-013-0830-8" xlink:type="simple">10.1007/s10157-013-0830-8</ext-link></comment> <object-id pub-id-type="pmid">23843034</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fauci</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Haynes</surname> <given-names>BF</given-names></name>, <name name-style="western"><surname>Katz</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Wolff</surname> <given-names>SM</given-names></name> (<year>1983</year>) <article-title>Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years</article-title>. <source>Ann Intern Med</source> <volume>98</volume>: <fpage>76</fpage>–<lpage>85</lpage> <object-id pub-id-type="pmid">6336643</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Flossmann</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Berden</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>de Groot</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hagen</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Harper</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Heijl</surname> <given-names>C</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Long-term patient survival in ANCA-associated vasculitis</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>: <fpage>488</fpage>–<lpage>494</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/ard.2010.137778" xlink:type="simple">10.1136/ard.2010.137778</ext-link></comment> <object-id pub-id-type="pmid">21109517</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Keogh</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Ytterberg</surname> <given-names>SR</given-names></name>, <name name-style="western"><surname>Fervenza</surname> <given-names>FC</given-names></name>, <name name-style="western"><surname>Carlson</surname> <given-names>KA</given-names></name>, <name name-style="western"><surname>Schroeder</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Specks</surname> <given-names>U</given-names></name> (<year>2006</year>) <article-title>Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial</article-title>. <source>Am J Respir Crit Care Med</source> <volume>173</volume>: <fpage>180</fpage>–<lpage>187</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.200507-1144OC" xlink:type="simple">10.1164/rccm.200507-1144OC</ext-link></comment> <object-id pub-id-type="pmid">16224107</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hoffman</surname> <given-names>GS</given-names></name>, <name name-style="western"><surname>Kerr</surname> <given-names>GS</given-names></name>, <name name-style="western"><surname>Leavitt</surname> <given-names>RY</given-names></name>, <name name-style="western"><surname>Hallahan</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Lebovics</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Travis</surname> <given-names>WD</given-names></name>, <etal>et al</etal>. (<year>1992</year>) <article-title>Wegener granulomatosis: an analysis of 158 patients</article-title>. <source>Ann Intern Med</source> <volume>116</volume>: <fpage>488</fpage>–<lpage>498</lpage> <object-id pub-id-type="pmid">1739240</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Berden</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Goceroglu</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jayne</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Luqmani</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Rasmussen</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Bruijn</surname> <given-names>JA</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Diagnosis and management of ANCA associated vasculitis</article-title>. <source>Bmj</source> <volume>344</volume>: <fpage>e26</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.e26" xlink:type="simple">10.1136/bmj.e26</ext-link></comment> <object-id pub-id-type="pmid">22250224</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Westman</surname> <given-names>KW</given-names></name>, <name name-style="western"><surname>Bygren</surname> <given-names>PG</given-names></name>, <name name-style="western"><surname>Olsson</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ranstam</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Wieslander</surname> <given-names>J</given-names></name> (<year>1998</year>) <article-title>Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement</article-title>. <source>J Am Soc Nephrol</source> <volume>9</volume>: <fpage>842</fpage>–<lpage>852</lpage> <object-id pub-id-type="pmid">9596082</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Knight</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Askling</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Ekbom</surname> <given-names>A</given-names></name> (<year>2002</year>) <article-title>Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis</article-title>. <source>Int J Cancer</source> <volume>100</volume>: <fpage>82</fpage>–<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ijc.10444" xlink:type="simple">10.1002/ijc.10444</ext-link></comment> <object-id pub-id-type="pmid">12115591</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Faurschou</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sorensen</surname> <given-names>IJ</given-names></name>, <name name-style="western"><surname>Mellemkjaer</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Loft</surname> <given-names>AG</given-names></name>, <name name-style="western"><surname>Thomsen</surname> <given-names>BS</given-names></name>, <name name-style="western"><surname>Tvede</surname> <given-names>N</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients</article-title>. <source>J Rheumatol</source> <volume>35</volume>: <fpage>100</fpage>–<lpage>105</lpage> <object-id pub-id-type="pmid">17937462</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heijl</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Harper</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Flossmann</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Stucker</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Scott</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Watts</surname> <given-names>RA</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials</article-title>. <source>Ann Rheum Dis</source> <volume>70</volume>: <fpage>1415</fpage>–<lpage>1421</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/ard.2010.145250" xlink:type="simple">10.1136/ard.2010.145250</ext-link></comment> <object-id pub-id-type="pmid">21616914</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zycinska</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Kostrzewa-Janicka</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Nitsch-Osuch</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wardyn</surname> <given-names>K</given-names></name> (<year>2013</year>) <article-title>Cancer incidence in pulmonary vasculitis</article-title>. <source>Adv Exp Med Biol</source> <volume>788</volume>: <fpage>349</fpage>–<lpage>353</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/978-94-007-6627-3_47" xlink:type="simple">10.1007/978-94-007-6627-3_47</ext-link></comment> <object-id pub-id-type="pmid">23835997</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Silva</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Seo</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Schroeder</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Stone</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Merkel</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Hoffman</surname> <given-names>GS</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort</article-title>. <source>Arthritis Rheum</source> <volume>63</volume>: <fpage>2495</fpage>–<lpage>2503</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.30394" xlink:type="simple">10.1002/art.30394</ext-link></comment> <object-id pub-id-type="pmid">21484770</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Holle</surname> <given-names>JU</given-names></name>, <name name-style="western"><surname>Gross</surname> <given-names>WL</given-names></name>, <name name-style="western"><surname>Latza</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Nolle</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Ambrosch</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Heller</surname> <given-names>M</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades</article-title>. <source>Arthritis Rheum</source> <volume>63</volume>: <fpage>257</fpage>–<lpage>266</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.27763" xlink:type="simple">10.1002/art.27763</ext-link></comment> <object-id pub-id-type="pmid">20862686</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Talar-Williams</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Hijazi</surname> <given-names>YM</given-names></name>, <name name-style="western"><surname>Walther</surname> <given-names>MM</given-names></name>, <name name-style="western"><surname>Linehan</surname> <given-names>WM</given-names></name>, <name name-style="western"><surname>Hallahan</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Lubensky</surname> <given-names>I</given-names></name>, <etal>et al</etal>. (<year>1996</year>) <article-title>Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis</article-title>. <source>Ann Intern Med</source> <volume>124</volume>: <fpage>477</fpage>–<lpage>484</lpage> <object-id pub-id-type="pmid">8602705</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mahr</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Heijl</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Le Guenno</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Faurschou</surname> <given-names>M</given-names></name> (<year>2013</year>) <article-title>ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships</article-title>. <source>Best Pract Res Clin Rheumatol</source> <volume>27</volume>: <fpage>45</fpage>–<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.berh.2012.12.003" xlink:type="simple">10.1016/j.berh.2012.12.003</ext-link></comment> <object-id pub-id-type="pmid">23507056</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stroup</surname> <given-names>DF</given-names></name>, <name name-style="western"><surname>Berlin</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Morton</surname> <given-names>SC</given-names></name>, <name name-style="western"><surname>Olkin</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Williamson</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Rennie</surname> <given-names>D</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group</article-title>. <source>Jama</source> <volume>283</volume>: <fpage>2008</fpage>–<lpage>2012</lpage> <object-id pub-id-type="pmid">10789670</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stang</surname> <given-names>A</given-names></name> (<year>2010</year>) <article-title>Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses</article-title>. <source>Eur J Epidemiol</source> <volume>25</volume>: <fpage>603</fpage>–<lpage>605</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s10654-010-9491-z" xlink:type="simple">10.1007/s10654-010-9491-z</ext-link></comment> <object-id pub-id-type="pmid">20652370</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mantel</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Haenszel</surname> <given-names>W</given-names></name> (<year>1959</year>) <article-title>Statistical aspects of the analysis of data from retrospective studies of disease</article-title>. <source>J Natl Cancer Inst</source> <volume>22</volume>: <fpage>719</fpage>–<lpage>748</lpage> <object-id pub-id-type="pmid">13655060</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname> <given-names>N</given-names></name> (<year>1986</year>) <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source> <volume>7</volume>: <fpage>177</fpage>–<lpage>188</lpage> <object-id pub-id-type="pmid">3802833</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name> (<year>2002</year>) <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source> <volume>21</volume>: <fpage>1539</fpage>–<lpage>1558</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/sim.1186" xlink:type="simple">10.1002/sim.1186</ext-link></comment> <object-id pub-id-type="pmid">12111919</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage> <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey</surname> <given-names>Smith G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name> (<year>1997</year>) <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>Bmj</source> <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage> <object-id pub-id-type="pmid">9310563</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>O'Donovan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Perrett</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Montaner</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>YZ</given-names></name>, <name name-style="western"><surname>Harwood</surname> <given-names>CA</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Azathioprine and UVA light generate mutagenic oxidative DNA damage</article-title>. <source>Science</source> <volume>309</volume>: <fpage>1871</fpage>–<lpage>1874</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1114233" xlink:type="simple">10.1126/science.1114233</ext-link></comment> <object-id pub-id-type="pmid">16166520</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pedersen-Bjergaard</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Specht</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Larsen</surname> <given-names>SO</given-names></name>, <name name-style="western"><surname>Ersboll</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Struck</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hansen</surname> <given-names>MM</given-names></name>, <etal>et al</etal>. (<year>1987</year>) <article-title>Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy</article-title>. <source>Lancet</source> <volume>2</volume>: <fpage>83</fpage>–<lpage>88</lpage> <object-id pub-id-type="pmid">2885581</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Le Guenno</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Mahr</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Pagnoux</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Dhote</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Guillevin</surname> <given-names>L</given-names></name> (<year>2011</year>) <article-title>Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides</article-title>. <source>Arthritis Rheum</source> <volume>63</volume>: <fpage>1435</fpage>–<lpage>1445</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.30296" xlink:type="simple">10.1002/art.30296</ext-link></comment> <object-id pub-id-type="pmid">21337321</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Monach</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Arnold</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Merkel</surname> <given-names>PA</given-names></name> (<year>2010</year>) <article-title>Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review</article-title>. <source>Arthritis Rheum</source> <volume>62</volume>: <fpage>9</fpage>–<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.25061" xlink:type="simple">10.1002/art.25061</ext-link></comment> <object-id pub-id-type="pmid">20039416</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Roussou</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Dimopoulos</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Dimopoulos</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Anastasiou-Nana</surname> <given-names>MI</given-names></name> (<year>2008</year>) <article-title>Wegener's granulomatosis presenting as a renal mass</article-title>. <source>Urology</source> <volume>71</volume>: <fpage>547.e541</fpage>–<lpage>542</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.urology.2007.11.046" xlink:type="simple">10.1016/j.urology.2007.11.046</ext-link></comment> <object-id pub-id-type="pmid">18342212</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nath</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mant</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Luxton</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hughes</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Raju</surname> <given-names>KS</given-names></name>, <name name-style="western"><surname>Shepherd</surname> <given-names>P</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients</article-title>. <source>Arthritis Rheum</source> <volume>57</volume>: <fpage>619</fpage>–<lpage>625</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.22667" xlink:type="simple">10.1002/art.22667</ext-link></comment> <object-id pub-id-type="pmid">17471531</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ioannidis</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>CQ</given-names></name>, <name name-style="western"><surname>Schully</surname> <given-names>SD</given-names></name>, <name name-style="western"><surname>Khoury</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Freedman</surname> <given-names>AN</given-names></name> (<year>2014</year>) <article-title>Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses</article-title>. <source>Ann Oncol</source> <volume>25</volume>: <fpage>16</fpage>–<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/annonc/mdt372" xlink:type="simple">10.1093/annonc/mdt372</ext-link></comment> <object-id pub-id-type="pmid">24310915</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bosch</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Guilabert</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Espinosa</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Mirapeix</surname> <given-names>E</given-names></name> (<year>2007</year>) <article-title>Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review</article-title>. <source>Jama</source> <volume>298</volume>: <fpage>655</fpage>–<lpage>669</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.298.6.655" xlink:type="simple">10.1001/jama.298.6.655</ext-link></comment> <object-id pub-id-type="pmid">17684188</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weyand</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Goronzy</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Kurtin</surname> <given-names>PJ</given-names></name> (<year>2006</year>) <article-title>Lymphoma in rheumatoid arthritis: an immune system set up for failure</article-title>. <source>Arthritis Rheum</source> <volume>54</volume>: <fpage>685</fpage>–<lpage>689</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/art.21674" xlink:type="simple">10.1002/art.21674</ext-link></comment> <object-id pub-id-type="pmid">16508924</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zintzaras</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Voulgarelis</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Moutsopoulos</surname> <given-names>HM</given-names></name> (<year>2005</year>) <article-title>The risk of lymphoma development in autoimmune diseases: a meta-analysis</article-title>. <source>Arch Intern Med</source> <volume>165</volume>: <fpage>2337</fpage>–<lpage>2344</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/archinte.165.20.2337" xlink:type="simple">10.1001/archinte.165.20.2337</ext-link></comment> <object-id pub-id-type="pmid">16287762</object-id></mixed-citation></ref>
<ref id="pone.0126016.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fortin</surname> <given-names>PR</given-names></name> (<year>1996</year>) <article-title>Vasculitides associated with malignancy</article-title>. <source>Curr Opin Rheumatol</source> <volume>8</volume>: <fpage>30</fpage>–<lpage>33</lpage> <object-id pub-id-type="pmid">8867536</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>